High Growth CDMO RoslinCT is expanding its Hopkinton facility to support autologous and allogeneic cell therapy production, signaling growing capacity needs and potential for contract manufacturing partnerships and longer-term supply agreements.

Global Capability With cGMP suites in Edinburgh and Massachusetts and a heritage in stem cell tech, RoslinCT can serve multinational clients seeking cross-border manufacturing, process development, and regulatory-compliant scaling for advanced cell and gene therapies.

CRISPR Expertise The organization advanced the first CRISPR-edited stem cell therapy to marketing authorization, indicating strong genome editing capabilities that can be probed for partnerships in gene-edited cell therapies and early-stage development programs.

Leadership & Governance Recent board appointments and senior hires, including notable academic and industry figures, suggest a strategic push toward enterprise-grade commercial operations, business development focus, and expanded senior-level partnerships.

Financial Tightness Revenue is in the low single-digit millions, implying opportunities to engage around scale-up programs, pilot manufacturing, and value-based contracting as clients migrate from development to commercialization.